Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Potenza Therapeutics

- PMLiVE

Astellas promotes Anthony Fiordaliso to VP, Americas finance

He first joined the pharma firm in 2010 from Schering-Plough

- PMLiVE

CHMP recommends Teva’s generic version of Astellas’ Advagraf

Committee backs the drug for transplant rejection prophylaxis

- PMLiVE

FDA fast-tracks Astellas’ Rydapt rival

AML treatment gilteritinib is currently involved in four phase III trials

- PMLiVE

Amgen pledges $1.5bn for CytomX preclinical cancer drugs

Stellar valuations for immuno-oncology candidates continue

- PMLiVE

Astellas extends phase III programme for Rydapt rival gilteritinib

Japanese group hopes its AML drug will soon compete with Novartis' recently-approved treatment

Bristol Myers Squibb logo

BMS wins first US immuno-oncology paediatric licence

FDA gives the green light to expanded use of its melanoma treatment Yervoy

- PMLiVE

CHMP backs three immuno-oncology drugs for solid tumours

Roche, MSD and Merck/Pfizer are all on course for new European approvals later this year

Celgene building

Celgene joins PD-1 race via partnership with BeiGene

The pharma giant will pay the Chinese firm up to $980m in milestone payments

- PMLiVE

Pfizer hits accelerator on Xtandi trial in early prostate cancer

US pharma giant expects PROSPER trial results later this year

- PMLiVE

Astellas appoints new senior VP

Shontelle Dodson also takes on head of Medical Affairs Americas role

- PMLiVE

Activists torpedo Immunomedics deal with Seattle Genetics

venBio says deal will enrich CEO at shareholders' expense

Deal Watch March 2017

Sanofi, MedImmune, AstraZeneca, Astellas, Novartis and more feature in this month's pharma deals round-up

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links